Generic Drugs Market - Global Competitive Analysis
Ask For Table Of Content@
Competitive Analysis- Top 10 generic drug manufacturers, in terms of revenue, in 2016, are as follows:
1. TEVA PHARMACEUTICAL INDUSTRIES
2. MYLAN N.V.
3. NOVARTIS INTERNATIONAL AG
4. PFIZER, INC.
5. ALLERGAN PLC
6. SUN PHARMACEUTICALS
7. FRESENIUS KABI
8. ENDO INTERNATIONAL
9. LUPIN LIMITED
Teva Pharmaceuticals Industries strengthened its pole position in the generic drugs market through acquisition of the generic segment of Allergan, plc for US$ 40.5 billion in August 2016. This resulted in significant growth in revenue contribution of its generic drug segment, pegged at US$ 9.5 billion in 2016.
Mylan ranks second in the list of generic drug manufacturers, and this is due to the acquisition valued at US$ 7.2 Bn of Sweden’s Meda by Mylan, in year 2016. This also aided Mylan to increase its sales of over-the-counter drugs and expand its presence in new emerging markets such as China, Southeast Asia, Russia, and the Middle East.
Sandoz—Novartis Group’s business segment dealing in generic medicines—reported rampant growth of 9% Y-o-Y in 2016, in sales volume, with revenue pegged at US$ 9 Bn. However, it was partially offset by a 6% erosion in price. Pfizer is at the fourth position (US$ 4.6 Bn revenue in 2016). Pfizer acquired Hospira in 2015, in order to increase its product portfolio of both generic and branded products. Pfizer offers over 220 injectable medications, plus other off-brand products, which is expected to aid in gaining high revenue in near future. Patent loss of Viagra in 2017, will lead to significant generic competition from Teva and Mylan.
Allergan though ranked at fifth position, sold its generics assets to Teva in 2015, and the deal closed in August 2016, which takes the company out of the race for generic drug manufactures for 2017, till the company receives new approval for generic drug manufacturing. This can favor Aspen Pharma to enter the top 10 generic drug manufacturers league in 2017. Sun Pharmaceuticals Ltd., headquartered in Mumbai, India, generated over US$ 3.6 Bn in generic sales in 2016. Sun Pharmaceutical doubled its size by the acquisition of Ranbaxy Laboratories in 2015, thus expanding its product portfolio. However, growth was hampered when the FDA issued a warning letter in 2015 for the Halol, India, API plant, which supplies the generic products in the U.S. Owing to this, Sun Pharmaceuticals is unable to receive new generic drug approvals.
Fresunius Kabi, a generic arm of the Fresenius German Healthcare Group, reported a 4% growth in revenue from the U.S. in 2016 driven by strong sales of sterile injectable drugs. In 2017, the company entered into agreement to buy Akorn—a generic drugs manufacturer—for US$ 4.5 Bn, further strengthening its position in the market. For Endo Pharmaceuticals, till 2014, the generic segment did not generate significant revenue. However, following its acquisition of Par Pharmaceutical in 2015, revenue of Endo Pharmaceutical increased by 12.2% from 2012-2014. Following the acquisition, Endo enhanced its product portfolio with the addition of around 100 products, which also included profitable generic products.
Lupin, in 2016, completed acquisition of U.S.-based Gavis and obtained its first manufacturing site in the U.S., along with 60 ANDA filings pending approval with the FDA. This aided the company to increase its footprint in the highly lucrative U.S. market.
Increase in number of competitor’s for generic drugs market put the pressure on manufacturers of pricing. Moreover, price celling actions by respective governments is further aggravating the profit margins of generic drug manufacturers. Considering the challenges of pricing pressure as generics outfits feel the pinch with thin margins, the market is expected to exhibit steady growth in the future.
Being a very lucrative market with a number of patent expiries in the near future, it is essential for competitive analysis for market players. This could aid one in devising a unique strategy and process to sustain in this highly competitive generic drugs market.
Get More Details On this Report:
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Coherent Market Insights
1001 4th Ave,
Seattle, WA 98154
Visit our news Website: http://www.coherentnews.com
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Generic Drugs Market - Global Competitive Analysis here
News-ID: 920850 • Views: 214
More Releases from Pharamceutical
Interventional Oncology Solutions Market Ablation Radiofrequency Ablation, Cryo …
Interventional oncology is a field of medical science, which includes treatment and diagnosis of cancer and other problems related to cancer using minimally invasive procedures. Interventional oncology uses various techniques such as Ultrasound, computed tomography, X-ray, and magnetic resonance imaging (MRI) to treat tumors located in various organs of the body. Interventional oncology procedures are usually used to treat metastatic or primary cancer. These procedures can be used to treat
Congestive Heart Failure Drugs Market, by Drug Type ACE Inhibitors, Angiotensin …
Major driver for growth of the congestive heart failure drugs market is the robust pipeline of drugs under development. For instance, furosemide injection solution (SCP-101) sponsored by Johns Hopkins University in collaboration with Scpharmaceuticals Inc. was in phase 2 clinical trials in 2015, this injection is indicated for treatment of heart failure. Furosemide and Azosemide sponsored by Hyogo College of Medicine has completed phase 4 clinical trials in 2016, these
New improved medication with lesser side effects will drive the insomnia therape …
Benzodiazepines (BZP) such as temazepam and diazepam are the commonly prescribed medication for insomnia. Though these medications are effective, prolonged use of these drugs may cause cognitive impairment, dependency and addiction. The launch of novel drugs such as Intermezzo (2014), tasimelteon (2014) have created a meteoric growth in G7 countries in the insomnia therapeutics and is expected market over the forecast period. Intermezzo (2014), are used in small doses and administered
Antiepileptic Drugs Market - Global Industry Insights,
Antiepileptic Drugs Market Regional Analysis North America and Europe are expected to witness significant growth in the market over the forecast period due to robust pipeline for epilepsy treatment and individual efforts by leading manufacturers. For instance, Pfizer, Inc. entered into partnership with Epilepsy Foundation to find solutions for generic forms of epilepsy and associated neurological disorders in 2014. Asia Pacific region is expected to show positive developments over the forecast